Revolution Medicines (RVMD) News Today $54.24 -0.89 (-1.61%) (As of 11/18/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Brokerages Set Revolution Medicines, Inc. (NASDAQ:RVMD) Price Target at $61.00November 18 at 3:05 AM | americanbankingnews.comRevolution Medicines (RVMD) Receives a Buy from Bank of America SecuritiesNovember 15 at 4:15 PM | markets.businessinsider.comRevolution Medicines, Inc. (NASDAQ:RVMD) Receives Average Rating of "Buy" from BrokeragesRevolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) has been assigned an average recommendation of "Buy" from the twelve research firms that are presently covering the firm, Marketbeat.com reports. Eleven research analysts have rated the stock with a buy recommendation and one has issued aNovember 13, 2024 | marketbeat.comWhat is HC Wainwright's Estimate for RVMD FY2024 Earnings?November 13, 2024 | americanbankingnews.comWedbush Reduces Earnings Estimates for Revolution MedicinesNovember 12, 2024 | americanbankingnews.comRevolution Medicines (NASDAQ:RVMD) Sets New 52-Week High - Time to Buy?Revolution Medicines (NASDAQ:RVMD) Sets New 12-Month High - Still a Buy?November 11, 2024 | marketbeat.comPromising Outlook for Revolution Medicines: Buy Rating Backed by Strong RAS ON Inhibitor Progress and Financial StabilityNovember 11, 2024 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Revolution Medicines (RVMD)November 11, 2024 | markets.businessinsider.comFY2024 Earnings Estimate for RVMD Issued By HC WainwrightRevolution Medicines, Inc. (NASDAQ:RVMD - Free Report) - Research analysts at HC Wainwright dropped their FY2024 EPS estimates for Revolution Medicines in a research note issued to investors on Thursday, November 7th. HC Wainwright analyst R. Burns now anticipates that the company will post earniNovember 11, 2024 | marketbeat.comEquities Analysts Offer Predictions for RVMD FY2024 EarningsRevolution Medicines, Inc. (NASDAQ:RVMD - Free Report) - Wedbush lowered their FY2024 earnings per share estimates for Revolution Medicines in a research report issued on Thursday, November 7th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings per share of ($3.43) forNovember 11, 2024 | marketbeat.comDecoding Revolution Medicines Inc (RVMD): A Strategic SWOT InsightNovember 9, 2024 | finance.yahoo.comRevolution Medicines, Inc. (NASDAQ:RVMD) Q3 2024 Earnings Call TranscriptNovember 8, 2024 | insidermonkey.comBank of America Securities Keeps Their Buy Rating on Revolution Medicines (RVMD)November 8, 2024 | markets.businessinsider.comHC Wainwright Issues Negative Forecast for RVMD EarningsNovember 8, 2024 | americanbankingnews.comJPMorgan Chase & Co. Increases Revolution Medicines (NASDAQ:RVMD) Price Target to $63.00JPMorgan Chase & Co. upped their price target on Revolution Medicines from $54.00 to $63.00 and gave the stock an "overweight" rating in a research note on Thursday.November 7, 2024 | marketbeat.comHC Wainwright Brokers Decrease Earnings Estimates for RVMDRevolution Medicines, Inc. (NASDAQ:RVMD - Free Report) - Equities researchers at HC Wainwright lowered their Q3 2024 earnings estimates for shares of Revolution Medicines in a report issued on Monday, November 4th. HC Wainwright analyst R. Burns now forecasts that the company will earn ($0.89) peNovember 7, 2024 | marketbeat.comRevolution Medicines Inc (RVMD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...November 7, 2024 | finance.yahoo.comRevolution Medicines, Inc. (RVMD) Q3 2024 Earnings Call TranscriptNovember 6, 2024 | seekingalpha.comRevolution Medicines, Inc. 2024 Q3 - Results - Earnings Call PresentationNovember 6, 2024 | seekingalpha.comRevolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate ProgressNovember 6, 2024 | globenewswire.comRevolution Medicines Inc (RVMD) Q3 2024 Earnings Report Preview: What To Look ForNovember 6, 2024 | finance.yahoo.comRevolution Medicines (NASDAQ:RVMD) Sets New 1-Year High - What's Next?Revolution Medicines (NASDAQ:RVMD) Sets New 52-Week High - Still a Buy?November 5, 2024 | marketbeat.comRevolution Medicines to Participate in Upcoming Investor ConferencesNovember 5, 2024 | globenewswire.comRevolution Medicines price target raised to $62 from $56 at H.C. WainwrightNovember 5, 2024 | markets.businessinsider.comRevolution Medicines (RVMD) to Release Earnings on WednesdayRevolution Medicines (NASDAQ:RVMD) will be releasing earnings after the market closes on Wednesday, November 6, Zacks reports.October 31, 2024 | marketbeat.comAllspring Global Investments Holdings LLC Acquires 35,399 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)Allspring Global Investments Holdings LLC lifted its stake in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 1,109.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 38,589 shares of the compaOctober 31, 2024 | marketbeat.comRevolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024October 30, 2024 | globenewswire.comRevolution Medicines, Inc. (NASDAQ:RVMD) Shares Acquired by Raymond James & AssociatesRaymond James & Associates lifted its position in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 156.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 190,505 shares of the company's stock after purOctober 30, 2024 | marketbeat.comRevolution Medicines price target raised to $60 from $55 at OppenheimerOctober 29, 2024 | markets.businessinsider.comStifel Nicolaus Sticks to Its Buy Rating for Revolution Medicines (RVMD)October 29, 2024 | markets.businessinsider.comStifel Nicolaus Sticks to Its Buy Rating for Revolution Medicines (RVMD)October 29, 2024 | markets.businessinsider.comRevolution Medicines (RVMD) Gets a Buy from BarclaysOctober 29, 2024 | markets.businessinsider.comRevolution Medicines (RVMD) Gets a Buy from BarclaysOctober 29, 2024 | markets.businessinsider.comChina Universal Asset Management Co. Ltd. Has $1.46 Million Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)China Universal Asset Management Co. Ltd. grew its stake in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 65.7% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 32,127 shares of the company's stock after buying anOctober 29, 2024 | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Price Target Raised to $82.00 at GuggenheimGuggenheim boosted their price objective on Revolution Medicines from $72.00 to $82.00 and gave the stock a "buy" rating in a research note on Monday.October 28, 2024 | marketbeat.comPiper Sandler Sticks to Their Buy Rating for Revolution Medicines (RVMD)October 25, 2024 | markets.businessinsider.comRevolution Medicines presents initial data from RMC-9805 studyOctober 25, 2024 | markets.businessinsider.comRevolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal AdenocarcinomaOctober 25, 2024 | globenewswire.comPromising Advancements in Revolution Medicines’ RMC-6236 for PDAC: A Strong Buy RatingOctober 25, 2024 | markets.businessinsider.comRevolution Medicines (NASDAQ:RVMD) Stock Rating Reaffirmed by Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and issued a $61.00 price target on shares of Revolution Medicines in a report on Thursday.October 24, 2024 | marketbeat.comRevolution Medicines’ RMC-6236 Shows Promising Phase 1 Results, Buy Rating AffirmedOctober 24, 2024 | markets.businessinsider.comRevolution Medicines presents data from RMC-6236 Monotherapy StudyOctober 23, 2024 | markets.businessinsider.comRevolution Medicines (NASDAQ:RVMD) Stock Price Up 3.2% - Here's What HappenedRevolution Medicines (NASDAQ:RVMD) Shares Up 3.2% - Time to Buy?October 23, 2024 | marketbeat.comRevolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal AdenocarcinomaOctober 23, 2024 | globenewswire.comRevolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal AdenocarcinomaOctober 21, 2024 | globenewswire.comRevolution Medicines Inc Ordinary SharesOctober 19, 2024 | morningstar.comRevolution Medicines, Inc. (NASDAQ:RVMD) Given Consensus Recommendation of "Buy" by BrokeragesRevolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) has earned a consensus recommendation of "Buy" from the eleven brokerages that are currently covering the stock, Marketbeat Ratings reports. Ten analysts have rated the stock with a buy recommendation and one has issued a strong buy recomOctober 19, 2024 | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) Insider Stephen Michael Kelsey Sells 16,666 SharesOctober 17, 2024 | insidertrades.comRevolution Medicines (NASDAQ:RVMD) Sets New 12-Month High - Time to Buy?Revolution Medicines (NASDAQ:RVMD) Reaches New 1-Year High - Here's WhyOctober 16, 2024 | marketbeat.comInsider Selling: Revolution Medicines, Inc. (NASDAQ:RVMD) Insider Sells 16,666 Shares of StockRevolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) insider Stephen Michael Kelsey sold 16,666 shares of Revolution Medicines stock in a transaction on Monday, October 14th. The stock was sold at an average price of $49.49, for a total value of $824,800.34. Following the sale, the insider now directly owns 264,408 shares of the company's stock, valued at $13,085,551.92. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.October 16, 2024 | marketbeat.com Get Revolution Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for RVMD and its competitors with MarketBeat's FREE daily newsletter. Email Address Blackrock’s Sending THIS Crypto Higher on Purpose (Ad)It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development… YES, I WANT THE #1 CRYPTO NOW RVMD Media Mentions By Week RVMD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RVMD News Sentiment▼-0.010.57▲Average Medical News Sentiment RVMD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RVMD Articles This Week▼105▲RVMD Articles Average Week Get Revolution Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for RVMD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies KYMR News BNTX News TEVA News MRNA News BGNE News GMAB News SMMT News VTRS News PCVX News SRPT News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RVMD) was last updated on 11/18/2024 by MarketBeat.com Staff From Our PartnersTech funds are hemorrhaging cash: Sell this stock nowSomething very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | SponsoredCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Crypto 101 Media | SponsoredBuffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of...Golden Crest | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredTrump’s EPIC Stock Market RallyPutting HUGE gain chances in the hands of hardworking, patriotic Americans like YOU. In fact, according to ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revolution Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revolution Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RVMD Stock Alerts